MetaCap

Nkarta (NKTX) vs Retension Pharmaceuticals (RTSN)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Retension Pharmaceuticals is the larger company by market cap ($87.6 million vs $81.3 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

NKTX-49.56%RTSN-0.19%
+60%+2%-55%
Oct 9, 20261 yearNov 20, 2026
NKTX-49.56%RTSN-0.19%
+50%-2%-54%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

NKTX versus RTSN key metrics
MetricNKTXRTSN
Share price$1.14$10.51
Market cap$81.29M$87.57M
1-day change+1.34%-19.22%
YTD return-38.65%—
1-year return-36.94%—
5-year return-93.05%—
EPS (TTM)$-1.73$-2.61
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$0—
Net income (latest FY)$-104.08M—
52-week high$3.72$18.64
52-week low$1.11$9.23
Distance from 52-week high-69.49%-43.62%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+825.11%+391.63%
Average volume1.02M144.93K
Shares outstanding71.62M8.33M
Employees10812
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Nkarta

NKTX stock →

Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis.

Health Care · Biotechnology: Pharmaceutical Preparations · 108 employees

About Retension Pharmaceuticals

RTSN stock →

Retension Pharmaceuticals, Inc. operates as a clinical -stage biopharmaceutical company focused on developing medicines for the treatment of hypertension and other cardiovascular diseases.

Health Care · Biotechnology: Pharmaceutical Preparations · 12 employees

NKTX vs RTSN FAQ

Which is bigger, Nkarta or Retension Pharmaceuticals?

Retension Pharmaceuticals (RTSN) is larger, with a market capitalization of $87.57M compared with $81.29M for Nkarta (NKTX).

Are Nkarta and Retension Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons